These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1612 related articles for article (PubMed ID: 33706513)

  • 1. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
    Bharate SS
    J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitrosamine Impurities in Angiotensin Receptor Blockers.
    Shephard EA; Nawarskas JJ
    Cardiol Rev; 2020; 28(5):262-265. PubMed ID: 32467427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
    Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
    Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and Denmark.
    Eworuke E; Shinde MU; Hou L; Paterson JM; Jensen PB; Maro JC; Rai A; Pottegård A; Scarnecchia D; Liang Y; Johnson D; Platt RW; Lee H; Bradley MC
    Pharmacoepidemiol Drug Saf; 2024 Sep; 33(9):e5849. PubMed ID: 39289955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
    Monteiro MA; de Lima PC; Novotny TS; Santana DS; Lima MED; Dantas ASCL; Ferreira LODS; de Souza MN; Maranho RLDN; Ochs SM
    J Pharm Sci; 2023 May; 112(5):1305-1314. PubMed ID: 36657719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
    Charoo NA; Ali AA; Buha SK; Rahman Z
    AAPS PharmSciTech; 2019 Apr; 20(5):166. PubMed ID: 30989447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
    Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
    Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical Methodologies to Detect N-Nitrosamine Impurities in Active Pharmaceutical Ingredients, Drug Products and Other Matrices.
    Manchuri KM; Shaik MA; Gopireddy VSR; Naziya Sultana ; Gogineni S
    Chem Res Toxicol; 2024 Sep; 37(9):1456-1483. PubMed ID: 39158368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Full Evaporation Static Headspace Gas Chromatography Method with Nitrogen Phosphorous Detection for Ultrasensitive Analysis of Semi-volatile Nitrosamines in Pharmaceutical Products.
    Zheng J; Kirkpatrick CL; Lee D; Han X; Martinez AI; Gallagher K; Evans RK; Mudur SV; Liang X; Drake J; Buhler LA; Mowery MD
    AAPS J; 2022 Jan; 24(1):23. PubMed ID: 34993666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY: NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER.
    Tchernev G; Kordeva S
    Georgian Med News; 2023 Apr; (337):63-67. PubMed ID: 37354675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
    Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
    Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
    Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
    J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the Risk of Nitrosamine Contamination During Drug Product Blister Packaging.
    Zheng J; Brookes A; Moser J; Pfeffer H; Smith A
    J Pharm Sci; 2023 Sep; 112(9):2321-2325. PubMed ID: 37478970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Status of Angiotensin Receptor Blocker Recalls.
    Gunasekaran PM; Chertow GM; Bhalla V; Byrd JB
    Hypertension; 2019 Dec; 74(6):1275-1278. PubMed ID: 31630573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MULTIPLE BCCS AND DYSPLASTIC NEVI AFTER ACE INHIBITORS (ENALAPRIL/PERINDOPRIL): THE ROLE OF NITROSAMINE CONTAMINATION/AVAILABILITY AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR.
    Tchernev G; Kordeva S
    Georgian Med News; 2023 Feb; (335):90-94. PubMed ID: 37042596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.
    Akkaraju H; Tatia R; Mane SS; Khade AB; Dengale SJ
    Regul Toxicol Pharmacol; 2023 Mar; 139():105355. PubMed ID: 36792049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel method for monitoring of carcinogenic impurity of N-nitrosamine in nizatidine pharmaceutical products using ultra high-pressure liquid chromatography triple quadrupole mass spectrometry.
    Dhorajiya S; Goswami J; Dudhatra B; Thummar K
    Rapid Commun Mass Spectrom; 2024 Oct; 38(19):e9884. PubMed ID: 39129244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control.
    Tuesuwan B; Vongsutilers V
    J Pharm Sci; 2021 Sep; 110(9):3118-3128. PubMed ID: 33989680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques.
    Shaik KM; Sarmah B; Wadekar GS; Kumar P
    Crit Rev Anal Chem; 2022; 52(1):53-71. PubMed ID: 32691615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of genotoxic N-nitrosamines in active pharmaceutical ingredients and market authorized products in low abundance by means of liquid chromatography - tandem mass spectrometry.
    Vogel M; Norwig J
    J Pharm Biomed Anal; 2022 Sep; 219():114910. PubMed ID: 35779354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 81.